Cooper Cos. Shares Advance After Investor Urges CEO Replacement
Dow Jones2026/09/17 23:12By Katherine Hamilton
Cooper Cos. shares advanced on a report that activist investor Jana Partners wants the company to consider a sale and change its leadership.
The stock rose 3%, to $55.27, in after-hours trading Thursday. Through the close, shares were down 34% this year.
Jana Partners plans to push the contact-lens maker to replace its chief executive and weigh selling its core business, The Wall Street Journal reported.
The investor said the changes are needed to address chronic underperformance and inability to manage spending.
Jana has been building its stake in Cooper for roughly a year. It previously suggested Cooper consider strategic alternatives, including a potential deal to combine with rival Bausch + Lomb.
Earlier this month, Cooper reduced its annual outlook after shrinking its contact-lens inventory as part of a strategic review. The inventory reduction weighed on third-quarter results and is expected to create challenges in the current fourth quarter.
Sales in the most recent third quarter were below Wall Street estimates, with disappointing results in Cooper's contact lens business CooperVision.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 17, 2026 19:12 ET (23:12 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
This Isn’t a Crypto Crash. Fed Hike Bets Are Hitting Everything

The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar
Deutsche Bank believes that the continuously expanding chip trade surplus in Asia is becoming a supporting force for the US dollar, as related profits are increasingly being reinvested into the US stock market.

Roche's (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: Analysts predict peak annual sales could reach up to $14.5 billion
Roche's (RHHBY.US) new oral breast cancer drug has been approved by U.S. regulators, paving the way for this medication, which the pharmaceutical company hopes will transform the treatment of the disease.
